{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "NUTX",
  "name": "Nutex Health Inc.",
  "url": "https://frontierpicks.com/dossiers/NUTX/",
  "json_url": "https://frontierpicks.com/dossiers/NUTX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a6",
    "n": 6
  },
  "current_thesis": "Re-rating leg has stalled: NUTX closed $162.98 on 2026-07-17 after five straight down days, ~20% off the $204.00 high, giving back the June breakout that B. Riley's 2026-06-26 Buy/$290 initiation topped out. A $55.0M true-up of 18,950 ineligible IDR claims plus a live SEC probe of the same revenue line means the ~2026-07-30 Q2 print is the binary. The theme is maturing.",
  "invalidation_trigger": "A weekly close below $150 forfeits the spring base and the June breakout structure, reclassifying the March-to-June move as a completed squeeze. Secondary: a second true-up of ineligible IDR claims, a disclosed collection rate under 80%, or any SEC enforcement action on arbitration revenue.",
  "catalyst_date": "2026-09-09",
  "outcome": "INVALIDATED",
  "outcome_date": "2026-07-27",
  "invalidation_fired": true,
  "themes": [
    "managed-care-health-services",
    "squeeze-momentum-setups"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Float is small (~7M shares outstanding) with short interest last reported near 13.84%; single headlines have produced double-digit single-session moves in both directions.",
    "Q2 FY2026 EPS included HaloMD fee credits retroactive to the 2024-05-01 contract date, so the quarter is not a clean run-rate for the contract services line.",
    "The SEC inquiry into disclosure of HaloMD's legal exposure and arbitration-revenue collectibility is unresolved, alongside a securities class action and a derivative suit.",
    "50-60% of claims are routed through No Surprises Act IDR arbitration, so federal rulemaking or a CMS process change reprices the revenue model directly.",
    "A $55.0M cumulative true-up covering 18,950 ineligible IDR claims (Jul-2024 to Dec-2025) already sits in reported history; eligibility screens are applied retroactively.",
    "Roughly five sell-side analysts cover the name per aggregators; a single rating change moves the consensus target materially."
  ],
  "body_markdown": "\n_Refresh of coverage first published 2026-07-02; last updated 2026-08-15._\n\n## NUTX — Nutex Health, Inc.\n\n## Current Thesis\nThe post-print re-rating held, then stopped extending. NUTX closed $185.84 on 2026-08-21 against $187.42 on 2026-08-14 — six sessions of sideways action, 5.9% below the 52-week high of $197.51, with RSI(14) at 64.0 and a three-month price change of +56.3%. Nothing external arrived in that window: no rating change since Lake Street's 2026-08-11 raise to $310 from $235, no new filing, and the only company headline was the 2026-08-18 opening of a West Little Rock emergency hospital in Arkansas. The narrative content is unchanged from the 2026-08-06 print — the cost of collecting No Surprises Act arbitration revenue was structurally reset (contract services expense $1.1M in Q2 FY2026 against $61.1M a year prior, a $52.3M reduction, plus the CMS federal IDR administrative fee cut from $115 to $15 per party per dispute effective 2026-06-11) — but the flow behind it has moderated. The narrative is **maturing**. The prior accelerating label was dated to the 2026-08-06 print and the 2026-08-11 target raise; the conditions that supported it — fresh coverage, expanding participation, new highs — have not repeated in the seven sessions since, while the structure itself is intact. What is genuinely unresolved is whether the Q2 cost line was a retroactive credit or a run-rate, and that does not resolve until the Q3 print in early November.\n\n## Bull Case\n- **Cost relief is filed, not guided.** Contract services expense of $1.1M in Q2 FY2026 versus $61.1M a year earlier, disclosed in the 2026-08-06 release. The CMS fee cut to $15 per party per dispute took effect 2026-06-11 by rule.\n- **Cash conversion.** Six-month operating cash flow of $109.7M to 2026-06-30, up from $78.2M. Cash and cash equivalents $205.2M plus $1.9M restricted at 2026-06-30, against long-term debt net of $31.1M.\n- **Capacity is still being added.** The West Little Rock emergency hospital opened per the company release of 2026-08-18 — the third Arkansas facility, and characterised by Simply Wall St's 2026-08-20 piece as the 28th nationwide. Six-month visits 99,704, +6.2%, same-hospital +3.4%.\n- **Share count is shrinking, not growing.** $50.7M of common stock repurchased in the six months to 2026-06-30, following roughly $30.4M of insider purchases reported in the quarter ended 2026-03-31. No equity issuance into the August strength has been disclosed.\n- **Arbitration mechanics reaffirmed on the 2026-08-06 call:** 50–60% of claims routed through IDR, prevailing in over 85% of award determinations, collecting on average over 80% of award amounts.\n- **Published targets sit well above the tape.** B. Riley Buy/$290 (2026-06-26); Lake Street Buy/$310 (2026-08-11). Aggregators show roughly five covering analysts, average target near $266.40, high $310, low $200, against the 2026-08-21 close of $185.84.\n\n## Bear Case\n- **Q2 EPS is not a run-rate.** The HaloMD fee amendment moved certain fees to pay-on-collected terms retroactive to the original 2024-05-01 contract date, so the June quarter absorbed credits belonging to eight prior periods. A $1.1M contract services line does not repeat. The first clean read is the quarter ending 2026-09-30, reported in early November.\n- **Revenue keeps falling.** $216.5M in Q1 FY2026, $210.752M in Q2 — a 13.6% YoY decline from $244.0M and a miss against the $215.031M consensus. Visit growth of +9.6% did not offset arbitration mix.\n- **The $55.0M cumulative true-up of 18,950 ineligible IDR claims (Jul-2024 to Dec-2025) already sits in reported history.** Eligibility screens are applied retroactively, so the mechanism that produced one reset can produce another.\n- **Legal overhang unresolved.** The SEC inquiry into disclosure of HaloMD's legal exposure and arbitration-revenue collectibility remains open, alongside a securities class action and a derivative suit stemming from the 2025-07-22 Blue Orca short report.\n- **Regulatory dependence cuts both ways.** The same federal IDR process that delivered the fee cut sets claim eligibility; a rulemaking change reprices the revenue model directly.\n- **Coverage is thin enough to reverse.** Five houses carry the name. One downgrade from either B. Riley or Lake Street moves the consensus target materially and removes the bid that followed the print.\n\n## Setup & Price Structure\nReference close 2026-08-21: $185.84, with the 52-week high at $197.51 on the adjusted daily series. The structure runs: the 2026-07-17 close of $162.98 after five straight down days marked the failure of the June breakout; the 2026-08-06 print gapped price out of that stall — Simply Wall St put the post-print advance at +29.2% — and the tape has since consolidated in a narrow band beneath the August high rather than reversing. RSI(14) at 64.0 is elevated without being stretched.\n\nCrowding and positioning observables, stated as observables: sell-side coverage went from one house on 2026-06-26 to roughly five by 2026-08-11, an expansion of attention concentrated in seven weeks; the consensus target of ~$266.40 sits about 43% above the 2026-08-21 close, which is a wide gap for a name with an unresolved SEC inquiry; no earnings date falls inside the next 30 days; and the company has been buying stock rather than selling it, with $50.7M repurchased in the six months to 2026-06-30 and no disclosed issuance into strength. The float mechanics remain the dominant driver of single-session range — a single 8-K has repeatedly produced double-digit moves in both directions.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-09 (est.)** — Nasdaq publication of short interest for the 2026-08-31 settlement date. First reading that spans the entire post-print advance.\n- **2026-09-15 (est.)** — Nasdaq publication cycle for the mid-September settlement, if the prior reading shows a material change in the short base.\n- **2026-09-30** — Q3 FY2026 quarter-end. The first full period governed by both the amended HaloMD fee terms and the $15 CMS administrative fee. Falls just outside the 30-day window but sets the content of the November print.\n- No scheduled earnings, guidance event, investor conference or index rebalance affecting the name has been identified inside the 30-day window. The next hard binary is the Q3 report, estimated ~2026-11-05.\n\n## What Would Change Our Mind\nThe structure that matters now is the shelf built after 2026-08-06, not the June breakout that already failed once. Losing it would say the print was re-rated on a number the market subsequently decided was non-recurring. A weekly close below $162 forfeits the entire post-print advance and returns price into the July stall zone where the last breakout attempt died at the 2026-07-17 close of $162.98; that is the gradeable break.\n\nThree non-price conditions would change the read independently of the tape. First, the Q3 FY2026 print showing contract services expense returning toward the $61.1M pre-amendment level rather than settling at a materially lower normalized figure — this is the single number that decides whether the earnings inflection is structural. Second, any further disclosed reversal of previously recognized arbitration revenue, in a 10-Q or 8-K, which would convert the $55.0M true-up from a one-time cleanup into a recurring reset. Third, escalation of the SEC inquiry — a Wells notice, an enforcement action, or an Item 4.02 non-reliance filing.\n\nConditions that would move the label back to accelerating: a close above the $197.51 52-week high on expanding volume, a sixth covering analyst, or a short-interest reading for the 2026-08-31 settlement showing the base rebuilt against a ~7M share count.\n\n## Correlation Notes\n- Correlation to large hospital operators (HCA, THC, UHS) is weak in practice: those names trade on admissions volume, payer mix and labour cost, while NUTX's earnings swing in Q2 FY2026 came from an arbitration-vendor fee amendment and a CMS administrative fee schedule.\n- The genuine shared factor is federal No Surprises Act IDR policy, which it holds with air-ambulance and physician-staffing operators exposed to out-of-network arbitration. A CMS/DOL/HHS rulemaking headline moves that cohort together.\n- HaloMD is private, so there is no listed proxy for the counterparty whose fee structure drove the Q2 result; the only read-through arrives through Nutex's own filings.\n- With roughly 7M shares outstanding and short interest last reported near 13.84%, index and small-cap flow can dominate the daily print independently of fundamentals; day-to-day moves should not be read as information about the arbitration model.\n- The stock's beta to its own single-headline risk is far higher than its beta to any sector index — the July drawdown and the August advance were both company-specific and neither tracked healthcare-sector moves.",
  "first_seen": "2026-07-02",
  "last_analyzed": "2026-08-23T14:42:42+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}